The Priority Review

Approvals Brief

FDA approves first drug to treat adults with primary membranous nephropathy

The FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression to induce remission of proteinuria. In the MAJESTY Phase 3 study, 36% of patients achieved complete remission at week 104 versus 6% with tacrolimus.

Primary source

FDA approval notification, November 13, 2026

FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy

Read the source: FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy fda.gov

Machine-summarized from the source above; not independently reported. How we use automation